A hospital based study on causes peculiar of congestive cardiac failure(CCF)

Objective:To determine the frequency of risk factors of congestive cardiac failure in a tertiary care hospital of Peshawar.Methods:This retrospective observational study was conducted in department of Cardiology,Postgraduate Medical Institute,Lady Reading Hospital Peshawar,from March 2005 to September 2007.Relevant information regarding the risk factors of congestive cardiac failure were recorded on questionnaire prepared in accordance with the objectives of the study.Results:1 019 patients with established diagnosis of cardiac failure (based on clinical findings and relevant investigations) were included.Out of total sampling 583 (57.12%) were males and 436(42.78%) were females.The age range of the patients was from 6 years to 82 years with mean age of 48.5 years and mode of age was 45 years.The distribution of causative factors of CCF was:ischemic heart disease(IHD) 36.31%,hypertension 26.30%,dilated cardiomyopathy 10.10%,obstructve and restrictive cardiomyopathies 5.39%,valvular heart diseases(VHD) 9.32%,congenital heart disease like ventricular septal defects(VSD) 4.41%,atrial septal defects(ASD) 0.58%,atrial fibrillation (AF) 2.25%,constrictive pericardidtis 1.07%.Pericardial effusion 0.68%,chronic obstructive pulmonary disease and pulmonary hypertension 1.47%,thyrotoxicosis 0.68%,complete heart block 0.29%and paget disease in 0.09%cases.Conclusion:Ischemic heart disease,hypertension,cardiomypathies,valvular heart disease and congenital heart disease are major contributor to CCF in our patients.

Echocardiographic Evaluation of Cardiac Dyssynchrony in Patients with Congestive Heart Failure

The present study investigated the application of echocardiography to evaluation of cardiac dyssynchrony in patients with congestive heart failure（CHF）. A total of 348 consecutive CHF patients who were admitted for cardiac resynchronization（CRT） and presented with low ejection fraction（EF） and wide QRS duration were enrolled in this study, along with 388 healthy individuals. Dyssynchrony was assessed based on filling time ratio（FT/RR）, left ventricular pre-ejection delay（PED）, interventricular mechanical delay（IVMD）, longitudinal opposing wall delay（LOWD） and radial septal to posterior wall delay（RSPWD）. Response to CRT was defined as a ≥15% increase in EF. The results showed that FT/RR was decreased while PED, IVMD, LOWD and RSPWD were increased in the CHF group compared with the control group（P〈0.01）. In the CHF group, FT/RR was negatively correlated with the QRS duration, LV end-diastolic diameter（LVESd）, LV end-diastolic volume（LVEDV） and LV end-systolic volume（LVESV）（P〈0.01）, but positively with the LVEF（P〈0.01）. Additionally, PED, IVMD, LOWD and RSPWD were positively correlated with the QRS duration, LVESd, LVEDV and LVESV（P〈0.01）, but negatively with the LVEF（P〈0.01）. The CHF group was divided into three subgroups according to the varying degrees of LVEF. FT/RR decreased successively from the LVEF-1 group to the LVEF-2 group to the LVEF-3 group, while the PED, IVMD, LOWD and RSPWD successively increased in the same order（P〈0.01）. The CHF group was divided into three subgroups according to the varying degrees of QRS duration, and FT/RR decreased successively in a sequence from the QRS-1 group to the QRS-2 group to the QRS-3 group, while the PED, IVMD, LOWD and RSPWD successively increased in the same order（P〈0.01）. Speckle tracking radial dyssynchrony ≥130 ms was predictive of an EF response in patients in QRS-1 group（78% sensitivity, 83% specificity）, those in QRS-2 group（83% sensitivity, 77% specificity） and in QRS-3 group（89% sensitivity, 79% specificity）. In conclusion, echocardiography is a convenient and sensitive method for evaluating cardiac dyssynchrony in patients with CHF.

Improved Cardiac Contractility of Human Recombinant Growth Hormone on the Congestive Heart Failure of Pig

The enhanced cardiac contractility effect of human recombinant growth hormone (hr-GH) on the congestive heart failure (CHF) was studied on the pig. To build a pig model of congestive heart failure, a temporary artificial cardiac pacemaker was implanted in the pig’s body and paced at 220 beats to 240 beats per minute for 1 week. After the model of congestive heart failure was successfully set up, the frequency of the pacemaker was changed to 150 beats to 180 beats per minute to maintain the CHF model stable. Pigs were divided into three groups: The hr-GH group in which 0.5 mg/kg per day of hr-GH was administrated intramuscularly for 15 days, the injection control group in which an equal amount of physiological saline was injected intramuscularly, and a normal control group. The left ventricular diastolic end pressure was (10.60±2.41) mmHg in the hr-GH group, but (19.00±3.81) mmHg in the saline control group (P<0.01); Cardiac output was (1.86±0.13) L/min in the hr-GH group, but (1.56±0.18) L/min in the saline control group (P<0.05); Peripheral vascular resistance was (56.88±7.51) mmHg·(L/min) -1 in the hr-GH group, whereas (70.30±11.59) mmHg·(L/min) -1 in the saline control group (P<0.05); +dp/dt max was (2900±316.23) and (2280±286.36) in the hr-HG group and the saline control group respectively (P<0.05). The results show that hr-GH enhances myocardial contractility of CHF, and the CHF model built by a temporary artificial cardiac pacemaker at a high rate of stimulation is reasonable and applicable.

Intervention Effect of Jianxin Decoction (健心汤) on Serum Cytokine Level of Congestive Heart Failure Patients

Objective: To investigate the intervention effect of Jianxin Decoction (健心汤, JXD) on the cytokine level in serum of patients with congestive heart failure (CHF). Methods; Sixty-six patients with CHF were randomly divided into the control group (n = 33) and the trial group (n = 33). The control group received conventional treatment, and the trial group was treated with conventional therapy plus JXD for 4 weeks. Before and after treatment, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and nitrogen monoxide (NO) in serum and cardiac function were determined. Results: After treatment, the levels of TNF-α, IL-6 and NO were significantly lower than those before treatment (P<0.05, or P<0.01) in the two groups, and the lowering degree of the indices in the trial group was more significantly reduced than that in the control group (P<0.05). And cardiac functions in both groups were improved significantly (P<0.05, or P< 0.01). Conclusion: JXD could prevent and reverse ventricular remodeling so as to ameliorate cardiac function through regulating the levels of cytokines.

Effects of thyroxine on cardiac function and lymphocyte β-adrenoceptors in patients with chronic congestive heart failure

Objective To explore the effects of thyroid hormone (TH) on cardiac function and peripheral lymphocyte β-adrenoceptors (β-ARs) of patients with chronic congestive heart failure (CHF).Methods Twenty-eight patients with class III or IV advanced CHF due to dilated cardiomyopathy (DCM) or ischemic cardiomyopathy (ICM) were randomly divided into groups A and B. L-thyroxine (L-T50) was administered to group B. Exercise tolerance, chest X-rays, and echocardiographic parameters were obtained before and after one month of treatment, Ficoll-hypaque solution was used to separate peripheral lymphocytes, and 125l-pindolol radioligand binding was used to measure β-AR levels in peripheral lymphocytes.Results L-T50 therapy improved cardiac output [CO, (2. 98±0. 31 )L/min vs (3. 24 ±0. 28) L/min, P<0. 01], left ventricular ejection fraction (LVEF, 26.21%±3.21% vs 37.93% ±9.01%, P< 0. 01), and decreased isovolumetric relaxation time (IVRT, 0.12 ±0. 04 vs 0.10 ±0. 02, P<0. 01). Serum TH levels and the maximal number of β-AR binding sites (βmax) in peripheral lymphocytes were lower in patients with CHF than in normal healthy people, but L-T50 administration induced a β-AR up-regulation on peripheral lymphocyte surfaces. L-T50 was well tolerated without episodes of ischemia or arrhythmia. There was no significant change in heart rate or metabolic rate.Conclusion TH administration improves cardiac function and β-AR expression in peripheral lymphocytes of patients with CHF.

Complications of cardiac resynchronization therapy in patients with congestive heart failure

Background Previous clinical studies have suggested that patients with congestive heart failure and intraventricular conduction delay could benefit from cardiac resynchronization therapy （CRT）. Implantation of left ventricular lead is a complex procedure with some potential for complications. This study was conducted to analyse the complications of CRT in patients with congestive heart failure.Methods Totally 117 patients, 86 males and 31 females, mean age of 53 years, with congestive heart failure and intraventricular conduction delaywere enrolled in this study. Venography was performed on all patients. Different types of coronary sinus leads were used to pace the left ventricle.Results Left ventricular lead was attempted to implant through coronary sinus for all the 117 patients and was successfully implanted in 111 patients. The success rate was 94.9%. Main complications rate was 6.8%, including coronary sinus dissection in 4 patients, phrenic nerve stimulation required lead repositioning in 2 patients and lead dislodgement in 2 patients.Conclusions It is feasible and safe to pace left ventricle through coronary sinus. However, there are some procedural complications.

Left univentricular pacing for cardiac resynchronization therapy using rate-adaptive atrioventricular delay

Objective To evaluate left univentricular （LUV） pacing for cardiac resynchronization therapy （CRT） using a rate-adaptive atrioven- tricular delay （RAAVD） algorithm to track physiological atrioventricular delay （AVD）. Methods A total of 72 patients with congestive heart failure （CHF） were randomized to RAAVD LUV pacing versus standard biventricular （BiV） pacing in a 1 ： 1 ratio. Echocardiography was used to optimize AVD for both groups. The effects of sequential BiV pacing and LUV pacing with optimized A-V （right atrio-LV） delay using an RAAVD algorithm were compared. The standard deviation （SD） of the S/R ratio in lead VI at five heart rate （HR） segments （Rs/R-SD5）, defined as the ＂tracking index,＂ was used to evaluate the accuracy of the RAAVD algorithm for tracking physiological AVD. Results TheQRS complex duration （132 ± 9.8 vs. 138± 10ms, P 〈 0.05）, the time required for optimization （21 ±5 vs. 50±8min, P〈 0.001）, the mitral regurgitant area （1.9 ± 1.1 vs. 2.5 ± 1.3 em2, P 〈 0.05）, the interventricular mechanical delay time （60.7 ± 13.3 ms vs. 68.3 ± 14.2 ms, P 〈 0.05）, and the average annual cost （13,200 ± 1000 vs. 21,600 ± 2000 RMB, P 〈 0.001） in the RAAVD LUV pacing group were significantly less than those in the standard BiV pacing group. The aortic valve velocity-time integral in the RAAVD LUV pacing group was greater than that in the standard BiV pacing group （22.7 ± 2.2 vs. 21.4 ± 2.1 cm, P 〈 0.05）. The Rs/R-SD5 was 4.08 ± 1.91 in the RAAVD LUV pacing group, and was significantly negatively correlated with improved left ventricular ejection fraction （LVEF） （ALVEF, Pearson＇s r = -0.427, P = 0.009）, and positively correlated with New York Heart Association class （Spearman＇s r - 0.348, P 0.037）. Conclusions RAAVD LUV pacing is as effective as standard BiV pacing, can be more physiological than standard BiV pacing, and can de- crease the average annual cost of CRT.

Health Promotion in Cardiac Rehabilitation Patients through the Use of a High-Intensity Interval Training Protocol

According to the American Heart Association’s (AHA) recent statistical update, over 2150 Americans die each day from cardiovascular disease (CVD), which equals approximately 1 death every 40 seconds;many of which were under the age of 65 years old [1]. In 2009, 386,324 people, 1 in 6 Americans, died as a result of coronary artery disease (CAD) alone [1]. They also estimate 150,000 people have “silent” heart attacks each year [1]. Even though the number of cardiovascular disease deaths has declined in the last 10 years, they still accounted for 32.3% of American deaths [1]. As a result, the AHA updated their 2020 goals to improve the nation’s cardiovascular health by 20% [1]. One of these methods is through the use of cardiac rehabilitation. Cardiac rehabilitation (CR) is a health promotion strategy to help return cardiac patients to their previous level of functioning, increase health, decrease comorbidities and promote education and lifestyle change. For select patients, another alternative exercise plan may exist to gain even better results. High intensity interval training (HIIT) has shown positive training results for athletes and many studies show that it may also be an effective exercise modality for many cardiac patients instead of the traditional circuit training method. This article will review current literature on the effects of HIIT on CR patients as well as a sample HIIT protocol for instituting this treatment with appropriate patients.

Cardiac resynchronization therapy in acute pulmonary edema: A case report

We are reporting a case of 71-year old lady with a dual chamber demand pacemaker,who developed acute pulmonary edema due to an acute left ventricular(LV)dysfunction and worsening in mitral valve regurgitation after atrioventricular nodal ablation for uncontrolled atrial fibrillation.This was attributed to right ventricular apical pacing leading to LV dyssynchronization.Patient dramatically improved within 12-24 h after upgrading her single chamber pacemaker to biventricular pacing.Our case demonstrates that biventricular pacing can be an effective modality of treatment of acute congestive heart failure.In particular,it can be used when it is secondary to LV dysfunction and severe mitral regurgitation attributed to significant dyssynchrony created by right ventricular pacing in patients with atrioventricular nodal ablation for chronic atrial fibrillation.

Cardiac Amyloidosis: The Role of Magnetic Resonance Imaging

Amyloidosis, an infiltrative disease characterized by deposition of high molecular weight insoluble protein has a low detection rate and poor prognosis with congestive heart failure being the most common cause of death. Although definitive diagnosis is based on endomyocardial biopsy, this is rarely performed due to procedural risk and sampling error. Traditional non-invasive imaging, such as transthoracic echocardiography (TTE) and electrocardiogram (ECG) lacks sensitivity detecting the disease in its early stages. This case report demonstrates the utility of cardiac Magnetic Resonance Imaging in addition to traditional imaging modalities in this often clinically challenging problem.

Signaling Pathways Involved in Cardiac Hypertrophy

Cardiac hypertrophy is the heart＇s response to a variety of extrinsic and intrinsic stimuli that impose increased biomechanical stress. Traditionally, it has been considered a beneficial mechanism; however, sustained hypertrophy has been associated with a significant increase in the risk of cardiovascular disease and mortality. Delineating intracellular signaling pathways involved in the different aspects of cardiac hypertrophy will permit future improvements in potential targets for therapeutic intervention. Generally, there are two types of cardiac hypertrophies, adaptive hypertrophy, including eutrophy （normal growth） and physiological hypertrophy （growth induced by conditioning）, and maladaptive hypertrophy, physical including pathologic or reactive hypertrophy （growth induced by pathologic stimuli） and hypertrophic growth caused by genetic mutations affecting sarcomeric or cytoskeletal proteins. Accumulating observations from animal models and human patients have identified a number of intracellular signaling pathways that characterized as important transducers of the hypertrophic response, including calcineurin/nuclear factor of activated Tcells, phosphoinositide 3-kinases/Akt （PI3Ks/Akt）, G protein-coupled receptors, small G proteins, MAPK, PKCs, Gp130/STAT3, Na＋/H＋ exchanger, peroxisome proliferator-activated receptors, myocyte enhancer factor 2/histone deacetylases, and many others. Furthermore, recent evidence suggests that adaptive cardiac hypertrophy is regulated in large part by the growth hormone/insulin-like growth factors axis via signaling through the PI3K/Akt pathway. In contrast, pathological or reactive hypertrophy is triggered by autocrine and paracrine neurohormonal factors released during biomechanical stress that signal through the Gq/phosphorlipase C pathway, leading to an increase in cytosolic calcium and activation of PKC.

探讨沙库巴曲缬沙坦联合曲美他嗪治疗慢性充血性心力衰竭的临床疗效及安全性

目的探讨沙库巴曲缬沙坦、曲美他嗪联用治疗慢性充血性心力衰竭的疗效及安全性。方法以76例慢性充血性心力衰竭患者为研究对象,按抽签法分为甲组及乙组,每组38例。甲组给予依那普利+曲美他嗪治疗,乙组给予沙库巴曲缬沙坦+曲美他嗪治疗。比较两组患者的治疗效果,心功能指标[左心室射血分数(LVEF)、N末端脑钠肽前体(NT-proBNP)水平及6 min步行试验距离(6MWD)、左心室舒张末期内径(LVEDD)],不良反应发生率及住院时间。结果乙组治疗总有效率97.37%高于甲组的81.58%,差异具有统计学意义(χ^(2)=5.0294,P=0.0249<0.05)。两组治疗前的LVEF、NT-proBNP、6MWD、LVEDD比较,差异无统计学意义(P>0.05);乙组治疗后的LVEF(51.27±5.65)%高于甲组的(47.84±5.25)%、NT-proBNP(867.87±66.56)pg/ml低于甲组的(911.26±76.98)pg/ml、6MWD(366.73±55.68)m长于甲组的(314.54±65.65)m、LVEDD(53.12±5.23)mm小于甲组的(56.76±5.78)mm,差异具有统计学意义(P<0.05)。乙组不良反应发生率低于甲组,但差异无统计学意义(P>0.05)。乙组住院时间(8.34±2.17)d短于甲组的(12.90±2.89)d,差异具有统计学意义(P<0.05)。结论沙库巴曲缬沙坦联用曲美他嗪治疗慢性充血性心力衰竭疗效确切,同时对心脏功能有明显的改善,是一种具有较好临床应用价值的治疗方案。

沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗慢性充血性心力衰竭的效果

目的分析沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗慢性充血性心力衰竭(CCHF)的有效性与安全性。方法选取2021年1月至2022年12月子长市人民医院内一科收治的80例CCHF患者作为研究对象,按照治疗方案不同将其分为单药组(n=40,琥珀酸美托洛尔缓释片治疗)和联合组(n=40,沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗)。比较两组的治疗效果。结果联合组的治疗总有效率显著高于单药组(P<0.05)。治疗后,联合组的左心室射血分数(LVEF)显著高于单药组,左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、舒张期室间隔厚度(IVST)显著小于单药组(P<0.05)。治疗后,联合组的N-末端B型利钠肽前体(NT-proBNP)、肿瘤坏死因子-α(TNF-α)、C-反应蛋白(CRP)、白细胞介素-6(IL-6)、细胞间黏附分子-1(ICAM-1)水平均显著低于单药组(P<0.05)。两组的不良反应总发生率无显著差异(P>0.05)。结论沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗CCHF的效果理想,可有效改善患者心功能与生化指标,且不增加药物不良反应,安全性高。

重组人脑利钠肽与米力农联合治疗急诊充血性心力衰竭的疗效及对患者血清NT-pro BNP、心功能指标的影响

目的探讨重组人脑利钠肽(rhBNP)联合米力农在急诊充血性心力衰竭(CHF)患者中的应用效果。方法回顾性分析2021年9月至2023年10月萍乡市人民医院收治的94例急诊CHF患者资料,按不同治疗方法分两组,各47例。对照组予以米力农治疗,观察组予米力农联合rhBNP治疗。对比两组临床疗效、血清学指标、心功能指标、心室重构指标及不良反应发生情况。结果观察组总有效率、左室射血分数、每搏输出量、左室质量指数高于对照组,N末端脑钠肽前体、血管紧张素Ⅱ、醛固酮、血浆肾素活性、超敏C反应蛋白、白介素-6、肿瘤坏死因子-α、左室收缩末内径、左室舒张末内径、左室后壁厚度、舒张期室间隔厚度低于对照组(P<0.05)。两组不良反应发生率相比差异无统计学意义(P>0.05)。结论rhBNP联合米力农可增强急诊CHF治疗效果,改善心功能与血清学指标,促进心室重构,且不良反应少。

充血性心力衰竭中医证治概述

充血性心力衰竭(CHF),又称慢性心力衰竭,是现今世界心血管领域的一大重要疾病,其发病率和病死率长期以来居高不下。近年来,中医在心力衰竭的临床治疗及科研方面均取得了较大进展。随着整个社会对中医关注度的提高,坚持中医的传承与创新越来越重要。此文概述了CHF的中医病名来源、病因病机沿革、中医证型与证候要素研究、基本治法方药总结,以期为现今中医对心力衰竭的临床治疗及科学研究提供理论参考和思路启迪。

达格列净在治疗2型糖尿病合并充血性心力衰竭中的安全性和有效性研究

目的评估达格列净在治疗2型糖尿病合并充血性心力衰竭患者中的安全性和有效性。方法选取2023年4月—2024年3月灌云县中医院收治的70例2型糖尿病合并充血性心力衰竭患者作为研究对象,根据不同的治疗方案分为对照组(n=33)和观察组(n=37)。对照组进行常规治疗,观察组在对照组的基础上进行达格列净治疗。比较两组患者临床治疗效果、血糖水平、心功能相关指标。结果观察组治疗有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组的空腹血糖、餐后2 h血糖、糖化血红蛋白水平均低于对照组,差异有统计学意义(P均<0.05)。观察组左心室射血分数、心输出量均高于对照组,N端脑钠肽前体低于对照组,差异有统计学意义(P均<0.05)。结论达格列净治疗2型糖尿病合并充血性心力衰竭,可改善患者的血糖水平和心功能,且安全性较高,治疗疗效显著。

沙库巴曲缬沙坦钠治疗慢性充血性心力衰竭的效果

目的:探讨沙库巴曲缬沙坦钠治疗慢性充血性心力衰竭的效果。方法:选取2022年2月—2023年2月安顺市镇宁布依族苗族自治县人民医院收治的慢性充血性心力衰竭患者100例为研究对象,随机分为对照组和试验组,各50例。对照组应用缬沙坦胶囊治疗,试验组应用沙库巴曲缬沙坦钠治疗。比较两组心功能[左心室射血分数(LVEF)、每搏输出量(SV)、心排血量(CO)]、生化指标[醛固酮(ALD)、血管生成素Ⅱ(AngⅡ)、去甲肾上腺素(NE)]、治疗效果。结果:治疗前,两组LVEF、SV、CO水平比较,差异无统计学意义(P>0.05);治疗后,两组LVEF、SV、CO水平升高,试验组高于对照组,差异有统计学意义(P<0.05)。治疗前,两组ALD、AngⅡ、NE水平比较,差异无统计学意义(P>0.05);治疗后,两组ALD、AngⅡ、NE水平降低,试验组低于对照组,差异有统计学意义(P<0.05)。试验组治疗总有效率高于对照组,差异有统计学意义(P<0.001)。结论:沙库巴曲缬沙坦钠治疗慢性充血性心力衰竭可以改善患者的心功能、生化相关指标,提高治疗效果。

国产左旋卡尼汀改善慢性充血性心力衰竭患者心功能的临床研究

目的 :观察国产左旋卡尼汀 (L - carnitine,L - CN )治疗充血性心力衰竭 (CHF)患者的临床疗效。方法 :选择慢性 CHF患者 5 6例 ,随机分为两组 :对照组 (2 8例 )给予洋地黄、利尿剂、血管扩张剂、ACEI或β受体阻滞剂等常规药物 ;L - CN组 (2 8例 )在常规治疗的基础上加用国产 L - CN治疗。结果 :L - CN组心功能改善的临床显效率 (4 2 .9% )和总有效率 (89.3% )均较对照组 (2 5 .0 %和 6 0 .7% )显著提高 (P<0 .0 1) ,且无不良反应出现。 结论 :用 L- CN辅助治疗

益气活血法对充血性心力衰竭患者疗效和心功能的影响

目的比较益气活血法、益气法、活血法治疗充血性心力衰竭患者的临床疗效和对心功能的影响。方法将80例患者随机分为3组,3组患者均在常规治疗下分别加入益气活血药(36例)、益气药(24例)及活血药(20例)。治疗2周后对3组患者临床疗效和心功能测定指标进行比较。结果临床疗效总有效率益气活血组(91．7％),分别与益气组(66．7％)、活血组(65．0％)比较,差异均有显著性(P<0．05．P< 0．01);心功能测定指标3组治疗前后比较,差异均有显著性(P<0．05,P<0．01);治疗后益气活血组与益气组、活血组比较,差异均有显著性(P<0．05)。结论3组治疗方法均可以改善临床症状、改善心功能,但益气活血法较单纯益气法、单纯活血法治疗效果更佳。

心肌组织速度成像对心脏再同步化治疗术后短期疗效的评价

目的应用常规超声心动图和心肌组织速度成像技术对心脏同步化治疗(CRT)的短期疗效进行评价。方法对18例心衰患者于三腔起搏器置人术前和术后1个月,应用Philips IE33分别测量左心室舒张末、收缩末的直径(LVDD、LVDS)、双平面Simpson's法测量左心室容积和射血分数(LVEF);心肌组织速度成像采集3个标准心尖切面图像,应用Q- lab分析软件测量左室基底部和中部12个节段收缩达峰时间的标准差(Ts-SD-12)及各节段心肌射血期峰值速度(Sm)、左室收缩后收缩(PSS)的峰值速度。结果心脏同步化治疗后,左室收缩同步性改善,Ts-SD-12减低,从(48.4±17.87)ms下降到(35.16±19.4)ms(P<0.05),左心室内径、容积缩小,收缩功能也有明显改善(P<0.05),各节段Sm明显提高(P<0.01)、PSS的峰值速度减低(P<0.05)。结论心肌组织速度成像技术是目前评价心肌再同步化治疗的有效手段。